Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.
Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.
advertisement
This is a familiar but tiring refrain.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
White House calls on federal agencies to crack down on AI abuses
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
